We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more Skip to Main Content

ID Week Virtual Issue

The Journal of Antimicrobial Chemotherapy (JAC) is among the foremost international journals in antimicrobial research. These high quality articles reach an international readership across North America, Asia and Europe, with 36% of usage in North America during 2015. Submit to the Journal of Antimicrobial Chemotherapy and benefit from:
  • Fast, efficient and rigorous peer-review
  • Post acceptance editorial quality and speed: average time from acceptance to online publication is 6.2 weeks*
  • Publication in a high impact journal, ranking 9/83 in Infectious Diseases**
"Speed and quality was outstanding. The editor's attention to detail was quite remarkable, really." - Contributor to JAC in 2015
*Average speed in 2016
**Thomson Reuters Journal Citation Reports 2016

Virtual Issue

To celebrate ID Week we have created a virtual issue of the Journal of Antimicrobial Chemotherapy. This issue is made up of top cited articles from North American authors from 2015 and 2016. These articles are freely available until 10th January 2017.

Explore the collection below:


Antibiotic research and development: business as usual? By S. Harbarth, U. Theuretzbacher, and J. Hackett on behalf of the DRIVE-AB consortium

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients By Norbert Heinrich et al

Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents By Suresh B. Lakshminarayana et al

Optimal timing of oral fosfomycin administration for pre-prostate biopy psrophylaxis By Nathaniel J. Rhodes et al

β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium By JR Smith et al


Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid By Katie E. Barber, Jordan R. Smith, Animesh Raut, and Michael J Rybak

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease By Oliver A Cornely et al

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria By Akinobu Ito et al

Validating hospital antibiotic purchasing data as a metric of inpatient antibiotic use By Charlie Tan, Michael Ritchie, Jason Alldred and Nick Daneman

A Phase 1b/2a study of the safety, pharmacokinetics and antiviral activity of BIT225 in patients with HIV-1 infection By John Wilkinson et al

Garrod Lecture

The 2016 Garrod Lecture: The role of the healthcare epidemiologist in antimicrobial chemotherapy—a view from the USA By John E. McGown Jr
This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Subscribe Now